Medicus Pharma (NASDAQ:MDCX) will present at the 2025 Bio International Convention on June 17.
Its lead asset, SkinJect, is in Phase 2 trials for basal cell carcinoma, with interim data showing over 60% clearance. The trial expanded to 90 US patients and is adding European sites. A separate 36-patient trial is underway in the UAE, led by Cleveland Clinic Abu Dhabi.
In April, Medicus signed a binding LOI to acquire UK-based Antev Ltd., developer of Teverelix, targeting advanced prostate cancer and acute urinary retention.